The Fund aims to achieve long-term capital growth.
Name | % Net Assets |
---|---|
GlaxoSmithKline PLC | 4.7% |
GlaxoSmithKline PLC | 4.6% |
Royal Dutch Shell PLC | 4.1% |
BG Group PLC | 3.9% |
Rio Tinto PLC | 3.3% |
British American Tobacco PLC | 3.0% |
HSBC Holdings PLC | 2.7% |
BT Group PLC | 2.5% |
Standard Chartered PLC | 2.4% |
Royal Dutch Shell PLC | 2.4% |
Key | % Net Assets |
---|---|
GlaxoSmithKline PLC | 4.7% |
GlaxoSmithKline PLC | 4.6% |
Royal Dutch Shell PLC | 4.1% |
BG Group PLC | 3.9% |
Other | 82.7% |
Date | 21-Nov-2024 |
---|---|
NAV | 198.09 |
Currency | EUR |
Change | 0.25 |
% | 0.13% |
YTD change | 10.85 |
YTD % | 5.79% |
Fund Inception | 01/07/2002 |
---|---|
Fund Manager | Dominic Baker |
TER | 1.67 (30-Mar-2012) |
Minimum Investment | |
---|---|
Initial | 500000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.05 |
You are here: research